A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02914938 |
|
Recruitment Status :
Recruiting
First Posted : September 26, 2016
Last Update Posted : February 8, 2018
|
Sponsor:
MEI Pharma, Inc.
Information provided by (Responsible Party):
MEI Pharma, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a two-arm, Phase 1b, open-label, dose escalation study of ME-401 alone and an open-label study of ME-401 in combination with rituximab in patients with relapsed/refractory B-cell malignancies.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL) Follicular Lymphoma (FL) Marginal Zone B Cell Lymphoma Diffuse Large B-cell Lymphoma (DLBCL) High Grade Non-Hodgkin's Lymphoma | Drug: ME-401 Drug: Rituximab | Phase 1 |
This is a two-arm, Phase 1b, open-label, dose escalation study of ME-401 alone and an open-label study of ME-401 in combination with rituximab in patients with relapsed/refractory B-cell malignancies. The two arms of the study will be conducted in parallel, with subject allocation to ME-401 alone or ME-401 plus rituximab based on disease type and availability of an open enrollment slot in the dose escalation arm.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 126 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | This is a two-arm, Phase 1b, open-label, dose escalation study of ME-401 alone and an open label study of ME-401 in combination with rituximab in patients with relapsed/refractory B-cell malignancies. The two arms of the study will be conducted in parallel, with subject allocation to ME-401 alone or ME-401 plus rituximab based on disease type and availability of an open enrollment slot in the dose escalation arm. |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Two-Arm, Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects With Relapsed/Refractory CLL, SLL, or FL and an Open-Label Study of ME-401 With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL |
| Study Start Date : | October 2016 |
| Estimated Primary Completion Date : | March 2020 |
| Estimated Study Completion Date : | July 2020 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Rituximab
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ME-401 Alone
This is an open label, dose escalation study with 4 planned dose levels of ME-401. There are 5 planned cohorts which each may enroll up to 12 subjects each.
|
Drug: ME-401 |
|
Experimental: ME-401 in Combination with Rituximab
This is an open-label study evaluating the safety, efficacy, and pharmacokinetics of ME-401 in combination with rituximab in patients with various B-cell malignancies. There are two planned cohorts which may enroll up to 72 subjects.
|
Drug: ME-401 Drug: Rituximab IV infusion 375 mg/m2
Other Name: Rituxan |
Primary Outcome Measures :
- Minimum Biologically Effective Dose (mBED) of ME-401 alone [ Time Frame: 1 year ]The mBED will be defined as the dose that is safe and that achieves an objective response rate that is not less than 30 %.
- Maximally Tolerated Dose (MTD) of ME-401 alone [ Time Frame: 1 year ]The MTD will be determined as the maximum dose that is safe. DLT rate closest to .25 and not to exceed 2 DLTs in 6 subjects
- Dose Limiting Toxicities (DLTs) of ME-401 alone [ Time Frame: within the first 56 days ]DLTs will be measured by the number of treatment related AEs that occur within the first 56 days of ME-401 administration, is considered clinically significant by the P.I. and occurs in the presence of supportive care
- Evaluate the safety and tolerability of ME-401 plus Rituximab [ Time Frame: 1 year ]Safety and tolerability will be measured by the number of treatment related AEs
Secondary Outcome Measures :
- Safety profile of ME-401 alone [ Time Frame: 1 year ]Safety profile will be measured by number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Efficacy of ME-401 alone as assessed by (OR) [ Time Frame: 2 years ]The efficacy of ME-401 alone will be assessed by the overall response (OR) of subjects calculated as the percent of subjects achieving a complete remission (CR) or a complete remission with incomplete marrow recovery (CRi) or a partial response (PR) according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL)
- Evaluate the PK of ME-401 alone (AUC) [ Time Frame: 2 years ]Determined by the Area Under the Concentration time curve (AUC)
- Evaluate the PK of ME-401 alone (Cmax) [ Time Frame: 2 years ]Determined by Peak Plasma Concentration (Cmax)
- Efficacy of ME-401 with Rituximab as assessed by (OR) [ Time Frame: 2 years ]The efficacy of ME-401 with Rituximab will be determined by the overall response of subjects calculated as the percent of subjects achieving a complete remission (CR) or a complete remission with incomplete marrow recovery (CRi) or a partial response (PR) according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL)
- Evaluate the PK of ME-401 with Rituximab (AUC) [ Time Frame: 2 years ]Determined by the Area Under the Concentration time curve (AUC)
- Evaluate the PK of ME-401 with Rituximab (Cmax) [ Time Frame: 2 years ]Determined by Peak Plasma Concentration (Cmax)
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria MEI-401 Alone:
- Diagnosis of relapsed/refractory CLL and/or relapsed/refractory SLL or FL
- No prior therapy with PI3Kd inhibitors
- No prior therapy with Bruton tyrosine kinase (BTK) inhibitors unless the subject was intolerant of BTK therapy
- Subject must have failed at least 1 prior therapy
- QT-interval corrected according to Fridericia's formula (QTcF) ≤ 450 milliseconds (ms)
- Left ventricular ejection fraction >50%
- For subjects, except those with CLL, must have at least one bi-dimensionally measurable nodal lesion >1.5 cm, as defined by Lugano Classification
- Willingness to participate in collection of pharmacokinetic samples
- A negative serum pregnancy test within 14 days of study Day 0, for females of childbearing potential
Inclusion Criteria ME-401 in Combination with Rituximab
-
Diagnosis of relapsed/refractory CLL SLL or FL, MZL, DLBCL and high-grade B-cell lymphoma. Subjects must meet the following criteria for relapsed or refractory disease:
- Relapsed disease: a subject who previously achieved a CR or PR, but demonstrated disease progression after a response duration of >6 months
- Refractory disease: a subject who demonstrated disease progression within 6 months of most recent therapy
- No prior therapy with PI3Kδ inhibitors
- No prior therapy with Bruton tyrosine kinase (BTK) inhibitors unless the subject was intolerant of BTK therapy
- Subjects with CLL, SLL, FL, and MZL must have a failure of at least 1 prior therapy and be considered by the investigator a candidate for therapy with a rituximab-based regimen; subjects with DLBCL and high-grade B-cell lymphoma must have a failure of at least 2 prior therapies.
- QT-interval corrected according to Fridericia's formula (QTcF) ≤450 milliseconds (ms)
- Left ventricular ejection fraction >50%
- For subjects, except those with CLL, must have at least one bi-dimensionally measurable nodal lesion >1.5 cm, as defined by Lugano Classification
- Willingness to participate in collection of pharmacokinetic samples
- A negative serum pregnancy test within 14 days of study Day 0 for females of childbearing potential
Exclusion Criteria:
- Known histological transformation from CLL to an aggressive lymphoma
- Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
- Subjects who have tested positive for hepatitis B surface antigen and/or hepatitis B core antibody
- Positive for hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody
- Ongoing drug-induced pneumonitis
- History of clinically significant cardiovascular abnormalities
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02914938
Contacts
| Contact: Lisa McColley | 402-238-2615 | lmccolley@clinipace.com | |
| Contact: Ben McOmber | 858-369-7125 | bmcomber@meipharma.com |
Locations
| United States, California | |
| Compassionate Care | Recruiting |
| Corona, California, United States, 92708 | |
| United States, New York | |
| Memorial Sloan Kettering Cancer Center | Recruiting |
| New York, New York, United States, 10065 | |
| Stony Brook | Recruiting |
| Stony Brook, New York, United States, 11794 | |
| United States, Ohio | |
| Cleveland Clinic | Recruiting |
| Cleveland, Ohio, United States, 44195 | |
| United States, Oklahoma | |
| Stephenson Cancer Center | Recruiting |
| Oklahoma City, Oklahoma, United States, 73104 | |
| United States, Tennessee | |
| Vanderbilt | Recruiting |
| Nashville, Tennessee, United States, 37240 | |
| United States, Washington | |
| Swedish Cancer Center | Recruiting |
| Seattle, Washington, United States, 98104 | |
| United States, Wisconsin | |
| Carbone Cancer Center | Recruiting |
| Madison, Wisconsin, United States, 53792 | |
| Switzerland | |
| lstituto Oncologico della Svizzera ltaliana Ospedale Regionale Bellinzona e Valli CH | Recruiting |
| Bellinzona, Switzerland | |
Sponsors and Collaborators
MEI Pharma, Inc.
| Responsible Party: | MEI Pharma, Inc. |
| ClinicalTrials.gov Identifier: | NCT02914938 History of Changes |
| Other Study ID Numbers: |
ME-401-002 |
| First Posted: | September 26, 2016 Key Record Dates |
| Last Update Posted: | February 8, 2018 |
| Last Verified: | February 2018 |
Additional relevant MeSH terms:
|
Lymphoma Lymphoma, Follicular Lymphoma, Non-Hodgkin Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, B-Cell, Marginal Zone Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders |
Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Leukemia Leukemia, B-Cell Rituximab Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |